A study evaluating safety and efficacy of azathioprine and romiplostim in combination as a rescue treatment in patients with acute or newly diagnosed refractory Immune Primary Thrombocytopenia

Trial Profile

A study evaluating safety and efficacy of azathioprine and romiplostim in combination as a rescue treatment in patients with acute or newly diagnosed refractory Immune Primary Thrombocytopenia

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Azathioprine (Primary) ; Romiplostim (Primary)
  • Indications Immune thrombocytopenic purpura; Thrombocytopenia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Jul 2017 New trial record
    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top